These products are estimated to have a generic market size of ZAR 165 million in the local market, the company said in a filing to the Bombay Stock Exchange (BSE). Aurobindo has a total of 31 marketing authorisations approved by the MCC, the company added.
Out of the nine products, Zinoxime and Yomax are anti-infective, while Auro-Lisinopril Co, Auro-Amlodipine and Lisinozide are cardio-vascular system drugs. The other products that received the approval include Auro-Finasteride, Zolid, Lazivir and Profina.